Literature DB >> 29336297

Add-on perampanel and aggressive behaviour in severe drug-resistant focal epilepsies.

S Juhl, G Rubboli.   

Abstract

This study aimed to investigate the incidence of aggressiveness in patients with severe drug-refractory focal epilepsy (DRE) who started perampanel (PER) as add-on treatment, and to identify possible predisposing factors. Data on 49 consecutive patients with severe DRE who initiated PER were retrospectively collected. Twelve of the 49 patients experienced aggressiveness as adverse event related to PER treatment, one third of them on low (2-4 mg/day) PER dosages. PER was discontinued in 10/12 patients because of aggressive behaviors. Aggressiveness could appear after several months or even more than one year of PER treatment. One third of patients with PER-related aggressiveness had intellectual disabilities and 5/12 patients took levetiracetam as a concomitant antiepileptic drug. Our study suggests that the occurrence of aggressive behaviors in patients with severe DRE is not uncommon during PER treatment and that it may occur after months or even years of treatment with a stable dosage, requiring PER discontinuation in the great majority of patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29336297      PMCID: PMC5762107     

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  19 in total

1.  A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment.

Authors:  Bernd Huber; Gaby Schmid
Journal:  Epilepsy Behav       Date:  2016-12-27       Impact factor: 2.937

2.  Evaluation of perampanel in patients with intellectual disability and epilepsy.

Authors:  Francesca M Snoeijen-Schouwenaars; Jans S van Ool; In Y Tan; Helenius J Schelhaas; Marian H J M Majoie
Journal:  Epilepsy Behav       Date:  2016-12-27       Impact factor: 2.937

3.  Clinical experience with perampanel: focus on psychiatric adverse effects.

Authors:  Helen Coyle; Peter Clough; Paul Cooper; Rajiv Mohanraj
Journal:  Epilepsy Behav       Date:  2014-10-30       Impact factor: 2.937

4.  Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.

Authors:  Marco Mula; Michael R Trimble; Josemir W Sander
Journal:  Epilepsia       Date:  2007-08-17       Impact factor: 5.864

5.  Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.

Authors:  Tracy Glauser; Antonio Laurenza; Haichen Yang; Betsy Williams; Tony Ma; Randi Fain
Journal:  Epilepsy Res       Date:  2015-12-01       Impact factor: 3.045

6.  A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria.

Authors:  Bernhard J Steinhoff; Hajo Hamer; Eugen Trinka; Andreas Schulze-Bonhage; Christian Bien; Thomas Mayer; Christoph Baumgartner; Holger Lerche; Soheyl Noachtar
Journal:  Epilepsy Res       Date:  2014-03-27       Impact factor: 3.045

7.  Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Authors:  Bernhard J Steinhoff; Elinor Ben-Menachem; Philippe Ryvlin; Simon Shorvon; Lynn Kramer; Andrew Satlin; David Squillacote; Haichen Yang; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2013-05-10       Impact factor: 5.864

8.  Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.

Authors:  Lieven Lagae; Vicente Villanueva; Kimford J Meador; Makarand Bagul; Antonio Laurenza; Dinesh Kumar; Haichen Yang
Journal:  Epilepsia       Date:  2016-05-25       Impact factor: 5.864

9.  Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.

Authors:  Alan B Ettinger; Antonia LoPresti; Haichen Yang; Betsy Williams; Sharon Zhou; Randi Fain; Antonio Laurenza
Journal:  Epilepsia       Date:  2015-07-03       Impact factor: 5.864

10.  Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register.

Authors:  Udo Carl Wieshmann; Gus A Baker
Journal:  BMJ Open       Date:  2013-03-19       Impact factor: 2.692

View more
  3 in total

1.  Hippocampal Proteomic Analysis in Male Mice Following Aggressive Behavior Induced by Long-Term Administration of Perampanel.

Authors:  Wu Yang; Lin Ma; Dong-Mei Hai; Ning Liu; Jia-Mei Yang; Xiao-Bing Lan; Juan Du; Li-Shan Yang; Tao Sun; Jian Qiang Yu
Journal:  ACS Omega       Date:  2022-06-01

Review 2.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

3.  The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents.

Authors:  Ming-Chi Lai; Ray-Chang Tzeng; Chin-Wei Huang; Sheng-Nan Wu
Journal:  Biomolecules       Date:  2019-10-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.